Nov 19, 2020 / 06:45PM GMT
Wai Kit Ma - Jefferies LLC, Research Division - Equity Associate
Hello, everyone. Welcome to the Jefferies London Virtual Health Care Conference. My name is Kit Ma. I would like to introduce our next company, GlycoMimetics, and the CEO, Rachel King.
This is going to be a standard presentation format, and after the presentation, if time allows, then we'll have a Q&A session. (Operator Instructions)
So with that, let me pass it to you, Rachel.
Rachel K. King - GlycoMimetics, Inc. - President, CEO & Director
Good. Thanks, Kit, and thanks for those of you who are listening to hear more about GlycoMimetics. Let me begin by making reference to the fact that I will be making forward-looking statements today, so I refer you to our regulatory filings for details.
I'd like to start by highlighting some of the key attributes of our late-stage pipeline and some of the upcoming catalysts that we have. Our most advanced program is uproleselan, which is currently enrolling in a Phase III trial in relapsed and refractory leukemia. This
GlycoMimetics Inc at Jefferies Virtual London Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers